Project cooperationUpdated on 23 January 2026
IMERETI — GMP Manufacturing & Advanced Therapies Development Partner
R&D Manager at Imereti
Madrid, Spain
About
----Seeking cooperation and offering services-----
With a strong commitment to scientific excellence, technological innovation, and process safety, IMERETI serves as a strategic partner for organizations seeking robust, compliant, and scalable solutions in regenerative medicine, cell and gene therapies, and next‑generation biomedical products.
IMERETI is a GMP‑certified pharmaceutical laboratory specializing in the design, development, and manufacturing of biological products and Advanced Therapy Medicinal Products (ATMPs). As the only laboratory in Spain authorized by the AEMPS to manufacture Platelet‑Rich Plasma (PRP) under GMP conditions, IMERETI provides high‑quality, regulatory‑aligned production for partners across the biomedical and biotech sectors.
Operating as a Contract Development & Manufacturing Organization (CDMO), IMERETI offers end‑to‑end services including sterile biological manufacturing, advanced therapy development, regulatory and quality consultancy, and specialized analytical services . Our facilities are located within Net‑Pharma (Madrid, Spain), Europe’s first pharmaceutical hub, providing a strategic logistical advantage and fostering collaboration with leading actors in the health innovation ecosystem.
Topic
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
Organisation
Similar opportunities
Project cooperation
Seeking collaboration in ATMP and New Approach Methodologies
- Partner seeks Consortium/Coordinator
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
Grzegorz Chodaczek
Immunotherapy Group Leader at Łukasiewicz Research Network - PORT Polish Center for Technology Development
Wrocław, Poland
Project cooperation
Computational prognosis of therapies for solid tumors
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Gianpaolo Ruocco
Professor and CEO at initiatives for Bio-Materials Behavior (iBMB) Srls
Potenza, Italy
Project cooperation
New in vitro assay methodologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Hanne Haslene-Hox
Seinor research scientist at SINTEF Industry
Trondheim, Norway